Loading...
•
Jun 30, 2021
AcelRx Q2 2021 Earnings Report
AcelRx reported second quarter 2021 financial results.
Key Takeaways
AcelRx Pharmaceuticals reported a net revenue of $0.4 million and a net loss of $9.9 million, or $0.08 per share for the second quarter of 2021. The company's cash and short-term investments balance was $55.3 million as of June 30, 2021. DSUVIA sales increased by 117% compared to Q1 2021.
DSUVIA sales increased by 117% compared to Q1 2021.
Entered into an agreement with Laboratoire Aguettant for DZUVEO commercialization in Europe, with potential for $55 million in milestone payments.
USAMMDA publicly communicated their support of DSUVIA for battlefield pain management.
Reached agreement with the FDA on corrective actions regarding a warning letter about DSUVIA promotional materials.
AcelRx
AcelRx
Forward Guidance
AcelRx is on track to exceed its guidance of 615 approvals by year end 2021 and plans to file New Drug Applications for two innovative pre-filled syringe product candidates within 12 months.
Positive Outlook
- Continued sales momentum with DSUVIA.
- Real-world data becoming more widely disseminated.
- Elective surgery restrictions easing.
- Commitment to investigator-initiated trials.
- Business development remains a key priority.
Challenges Ahead
- Uncertainties inherent in investigator-initiated studies.
- Possible material differences in actual results.
- Risks and uncertainties described in AcelRx’s reports filed with the SEC.
- Do not place undue reliance on any forward-looking statements.
- Financial information is in summary form only.